Labiotech.eu

News and Trends 16 Nov 2022

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.4 million) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (DTIF). Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Aelis Farma has announced positive results from its safety trials in healthy volunteers and the authorization to start the first trial in people with Down syndrome, with AEF0217, its drug candidate for the treatment of cognitive disorders. Aelis Farma is a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, made […]

November 15, 2022 - 4 minutesmins - By Liza Laws

Ilya Pharma enrols first patient in diabetic foot ulcer study

More News! 15 Nov 2022

Destiny Pharma’s XF-73 dermal infection project advances to safety study

The second of two planned preclinical safety studies has started for Destiny Pharma’s XF-73 dermal formulation. The company announced the start of an investigational new drug (IND) today (November 15) and is developing the formulation for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). This second study […]

November 15, 2022 - 2 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership

Jnana Therapeutics has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need. The company also announced the close of […]

November 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Researchers create mini ‘bone marrow in a dish’ to boost anti-cancer treatments

Scientists from Oxford University and the University of Birmingham in the U.K. have made the first bone marrow ‘organoids’ that capture the key features of human bone marrow. The technology, which is the subject of a patent application filed by University of Birmingham Enterprise, will allow for the screening of multiple anti-cancer drugs at the […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

Startup Scout 15 Nov 2022

Nagi Bioscience tests drugs on worms using microfluidics

The Swiss startup Nagi Bioscience aims to speed up drug and chemical safety testing by automating research on a worm called Caenorhabditis elegans. For companies developing a drug or chemical product, there are many ways to predict the safety of their compound in humans. They can test the drugs in cell cultures, which are cheap […]

November 15, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 15 Nov 2022

Bel Group and Standing Ovation partner on cheese proteins

Dairy giant Bel Group and start-up Standing Ovation are partnering on incorporating casein milk protein into Bel’s alternative cheese offerings. In September, Bel acquired an equity stake in Standing Ovation. Standing Ovation has developed a precision fermentation process that produces caseins of non-animal origin. These proteins are identical to those present in milk. Standing Ovation’s […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Potential new lead compounds for treatment of depression and anxiety disorders

Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

More News! 15 Nov 2022

Sequana Medical has positive results for heart failure therapy drug

Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […]

November 15, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

Researchers awarded £2M to develop drugs to prevent epileptic seizures in children

Scientists at Aston University in the U.K. have started work on a project that will look for new drug treatments to prevent the onset of childhood epilepsy. The three-year Medical Research Council (MRC) funded project is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, partnered with Bristol […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Avanzanite Bioscience looks to commercialize innovative medicines for rare diseases in Europe

Avanzanite Bioscience B.V. has officially launched its commercial-stage enterprise, to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The company’s business […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

First patient dosed in Nouscom colorectal cancer study

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Destiny Pharma’s XF-73 dermal infection project advances to safety study

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership

Researchers create mini ‘bone marrow in a dish’ to boost anti-cancer treatments

Nagi Bioscience tests drugs on worms using microfluidics

Bel Group and Standing Ovation partner on cheese proteins

Potential new lead compounds for treatment of depression and anxiety disorders

Sequana Medical has positive results for heart failure therapy drug

Researchers awarded £2M to develop drugs to prevent epileptic seizures in children

Avanzanite Bioscience looks to commercialize innovative medicines for rare diseases in Europe

First patient dosed in Nouscom colorectal cancer study

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!